Immunome Inc（IMNM）股票分析IMNMImmunome Inc

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immunome Inc is a good buy right now, trading at $17.99, significantly below the analyst price targets ranging from $24 to $37. The company has a strong cash position of $582.7 million, which is expected to fund operations into 2028, providing stability for future growth. Additionally, the recent FDA acceptance of the varegacestat application indicates potential for revenue growth, especially with the projected 84% reduction in disease progression risk shown in clinical trials. However, the main risk is the negative earnings trend, with a projected EPS of -0.67 for the next earnings date, which could impact investor sentiment.